Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stojadinovic, A.
Right arrow Articles by Singh, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stojadinovic, A.
Right arrow Articles by Singh, B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 19, Issue 10 (May), 2001: 2616-2625
© 2001 American Society for Clinical Oncology

Hürthle Cell Carcinoma: A Critical Histopathologic Appraisal

By Alexander Stojadinovic, Ronald A. Ghossein, Axel Hoos, Marshall J. Urist, Ronald H. Spiro, Jatin P. Shah, Murray F. Brennan, Ashok R. Shaha, Bhuvanesh Singh

From the Departments of Surgery and Pathology, and Laboratory of Epithelial Cancer Biology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Bhuvanesh Singh, MD, Head and Neck Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; email: singhb{at}mskcc.org

PURPOSE: Controversy exists over the ability of morphology to predict the biologic behavior of Hürthle cell carcinoma. The aim of this study was to conduct a critical histopathologic review of Hürthle cell carcinoma and to correlate morphologic parameters with clinical outcome.

PATIENTS AND METHODS: Patients with histologically confirmed Hürthle cell carcinoma treated between 1940 and 2000 form the basis of this study. Adenomas were excluded. Tumors of unknown malignant behavior ([UMB] n = 17) had solid growth pattern, incomplete capsular invasion (Ci), or both but no vascular invasion (Vi). Minimally invasive carcinomas ([MIC] n = 23) had one focus of intra- or extracapsular Vi, one focus of complete Ci, or both. Widely invasive carcinomas ([WIC] n = 33) demonstrated more than one focus of Vi, more than one focus of Ci, or both. The primary end points were relapse-free survival (RFS) and disease-specific survival (DSS). Rates of recurrence/death were estimated by Kaplan-Meier method. The univariate influence of prognostic factors on end points was analyzed by log-rank test, and multivariate analysis was performed by Cox regression.

RESULTS: Median follow-up was 8 years. No patients with UMB or MIC relapsed or died of disease. Of WIC, 73% relapsed and 55% died of disease. Age, size, and extent of resection did not influence outcome. Adverse predictors of RFS and DSS among WIC were extrathyroidal extension, nodal metastasis, positive margin, and solid growth pattern (P < .05). Both Ci and Vi were associated with worse DSS (P < .05). On multivariate analysis, extrathyroidal extension and nodal metastases were independent predictors of outcome (P < .05).

CONCLUSION: Patients with Hürthle cell carcinoma have a prognosis that is predicted by well-defined histomorphologic characteristics. Unlike differentiated thyroid cancer, nodal metastases predict a worse outcome in widely invasive Hürthle cell carcinoma, as does extrathyroidal extension.

A.S. and R.A.G. both contributed equally to this work.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
BMJ Case ReportsHome page
J. Samol and A. Waterston
Oxaliplatin-induced coronary artery spasm: first report of an important side-effect
BMJ Case Reports, February 26, 2009; 2009(feb24_1): bcr0620080334 - bcr0620080334.
[Abstract] [Full Text]


Home page
JNMHome page
D. A. Pryma, H. Schoder, M. Gonen, R. J. Robbins, S. M. Larson, and H. W.D. Yeung
Diagnostic Accuracy and Prognostic Value of 18F-FDG PET in Hurthle Cell Thyroid Cancer Patients
J. Nucl. Med., August 1, 2006; 47(8): 1260 - 1266.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
C. Ma, A. Kuang, J. Xie, and T. Ma
Possible Explanations for Patients with Discordant Findings of Serum Thyroglobulin and 131I Whole-Body Scanning
J. Nucl. Med., September 1, 2005; 46(9): 1473 - 1480.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
N. Bhattacharyya
Survival and Prognosis in Hurthle Cell Carcinoma of the Thyroid Gland
Arch Otolaryngol Head Neck Surg, February 1, 2003; 129(2): 207 - 210.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. Hoos, A. Stojadinovic, B. Singh, M. E. Dudas, D. H. Y. Leung, A. R. Shaha, J. P. Shah, M. F. Brennan, C. Cordon-Cardo, and R. Ghossein
Clinical Significance of Molecular Expression Profiles of Hurthle Cell Tumors of the Thyroid Gland Analyzed via Tissue Microarrays
Am. J. Pathol., January 1, 2002; 160(1): 175 - 183.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2001 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online